RonaldF.TutroneJr.MD

Urology • Baltimore, MD

RFT at CUA

Join to view full profile

Dr. Tutrone is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tutrone's full profile

Already have an account?

Office
6535 N Charles St
Suite 625
Baltimore, MD 21204
Phone+1 410-825-5454

Fax+1 410-825-5811

Education & Training

Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1989 - 1993
SUNY Downstate Health Sciences UniversityResidency, Surgery, 1987 - 1989
Rutgers Robert Wood Johnson Medical SchoolClass of 1987

Certifications & Licensure

MD State Medical License 1993 - 2025
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms Start of enrollment: 2009 Jun 01
Completed
Phase 3
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Terminated
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis Start of enrollment: 2014 Mar 01
Completed
Phase 2
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis Start of enrollment: 2015 Sep 23
Completed
Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer Start of enrollment: 2021 Jun 09
Terminated
Phase 1, Phase 2
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent Start of enrollment: 2021 Jun 24
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer.
Neal D Shore, Alicia K Morgans, Ronald F Tutrone
Future Oncology. 2024-12-01
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
Jeremie Calais, Michael J Morris, Ayse Tuba Kendi, Arash Rezazadeh Kalebasty, Ronald Tutrone
Journal of Nuclear Medicine. 2024-11-01
7 citations
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patient...
Fred Saad, Maha H A Hussain, Bertrand Tombal, Karim Fizazi, Cora N Sternberg
European Urology. 2024-10-01

Press Mentions

Baseball Legend Cal Ripken Jr. Says His Prostate Cancer 'Could Have Been a Much Different Result' if He Hadn't Been a Sports StarSeptember 22nd, 2020
Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility StudyMay 7th, 2020
'Missing Data' on Prostate Test: Good Science or Marketing War?May 29th, 2019
Join now to see all

Professional Memberships

American College of Surgeons - ACS
Member